Imaging tumor angiogenesis using 18F-Fluciclatide PET/CT in patients with colorectal and pancreatic cancer.

Imaging tumor angiogenesis using 18F-Fluciclatide PET/CT in patients with colorectal and pancreatic cancer. - 18F-Fluciclatide tumor imaging.

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON54757

Enrollment

Registered

2019-03-04

Start date

2021-06-24

Completion date

Unknown

Last updated

2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bowel cancer pancreatic cancer.

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Biopsy proven primary colorectal adenocarcinoma or suspected pancreatic ductal adenocarcinoma, as agreed on by multidisciplinary team; No prior chemo(radio)therapy in rectal cancer patients. Patients treated in the LUMC. Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations.

Exclusion criteria

Exclusion criteria: Contraindication for PET (pregnancy, breast-feeding and severe claustrophobia); Impaired renal function (creatinine clearance 3 ULN or total bilirubin >2x ULN); Known allergy to pABA (p-aminobenzoate sodium salt); Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; Inability to tolerate lying supine for the duration of a PET/CT examination (~30min).

Design outcomes

Primary

Measure	Time frame
Sensitivity/specificity of 18F-Fluciclatide.	—

Secondary

Measure	Time frame
Optimal imaging window of this tracer Feasibility of responsemonitoring with this tracer	—

Countries

Netherlands

Outcome results